Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)

Bibliography

• Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006;60:1454-70
   PubMed Web of Science ®Google Scholar
• Ahren B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab 2007;21:517-33
   PubMed Web of Science ®Google Scholar
• Richter B, Bandeira-Echtler E, Bergerhoff K, Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; published on line 2008/04/22; doi: 10.1002/14651858.CD006739.pub2CD006739
   Web of Science ®Google Scholar
• Palalau AI, Tahrani AA, Piya MK, DPP-4 inhibitors in clinical practice. Postgrad Med 2009;121:70-100
   PubMed Web of Science ®Google Scholar
• Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 2010;122:71-80
   PubMed Web of Science ®Google Scholar
• Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010;86:44-57
   PubMed Web of Science ®Google Scholar
• Monami M, Iacomelli I, Marchionni N, Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010;20:224-35
   PubMed Web of Science ®Google Scholar
• Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011;13:7-18
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA, Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
   PubMed Web of Science ®Google Scholar
• Drab SR. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 2010;30:609-24
   PubMed Web of Science ®Google Scholar
• Garber AJ. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. Am J Manag Care 2010;16:S187-94
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010;30:463-84
   PubMed Web of Science ®Google Scholar
• Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2010;19:133-40
   PubMed Web of Science ®Google Scholar
• Thomas L, Eckhardt M. Langkopf E, et al. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazoli n-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008;325:175-82
   PubMed Web of Science ®Google Scholar
• Tiwari A. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2009;10:1091-104
   PubMed Web of Science ®Google Scholar
• Scott LJ. Linagliptin: in type 2 diabetes mellitus. Drugs 2011;71:611-24
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-58
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49:573-88
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharmaceuticals. US Prescribing information Tradjenta (Linagliptin) tablets. [internet] 2011. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2011/201280lbl.pdf
   Google Scholar
• Fuchs H, Tillement JP, Urien S, Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol 2009;61:55-62
   PubMed Web of Science ®Google Scholar
• Fuchs H, Binder R, Greischel A. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos 2009;30:229-40
   PubMed Web of Science ®Google Scholar
• Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010;38:667-78
   PubMed Web of Science ®Google Scholar
• Huttner S, Graefe-Mody EU, Withopf B, Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008;48:1171-8
   PubMed Web of Science ®Google Scholar
• Retlich S, Duval V, Ring A, Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. Clin Pharmacokinet 2010;49:829-40
   PubMed Web of Science ®Google Scholar
• Sarashina A, Sesoko S, Nakashima M, Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Clin Ther 2010;32:1188-204
   PubMed Web of Science ®Google Scholar
• Horie Y, Kanada S, Watada H, Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients. Clin Ther 2011;33:973-89
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U, Giessmann T, Ring A, A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clin Ther 2011;33:1096-103
   PubMed Web of Science ®Google Scholar
• Graefe-Mody EU, Padula S, Ring A, Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin 2009;25:1963-72
   PubMed Web of Science ®Google Scholar
• Graefe-Mody EU, Jungnik A, Ring A, Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. Int J Clin Pharmacol Ther 2010;48:652-61
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U, Rose P, Ring A, Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects. Drug Metab Pharmacokinet 2011;26:123-9
   PubMed Web of Science ®Google Scholar
• Friedrich Ch MK, Rose P, Mattheus M, Pharmacokinetics and pharmacodynamics of BI 10773, a Sodium Glucose Cotransporter-2 (SGLT-2) inhibitor, and linagliptin, a Dipeptidyl Peptidase-4 (DPP-4) inhibitor, following co-administration in healthy volunteers. Diabetes 2011;60:abstract 2318-PO
   Google Scholar
• Graefe-Mody EU, Brand T, Ring A, Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Int J Clin Pharmacol Ther 2011;49:300-10
   PubMed Web of Science ®Google Scholar
• Friedrich C, Ring A, Brand T, Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. Eur J Drug Metab Pharmacokinet 2011;36:17-24
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U, Huettner S, Stahle H, Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. Int J Clin Pharmacol Ther 2010;48:367-74
   PubMed Web of Science ®Google Scholar
• Friedrich C, Port A, Ring A, Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: An open-label, two-period, fixed-sequence, multiple-dose study. Clin Drug Investig 2011;31:643-53
   PubMed Web of Science ®Google Scholar
• Heise T, Graefe-Mody EU, Huttner S, Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009;11:786-94
   PubMed Web of Science ®Google Scholar
• Forst T, Uhlig-Laske B, Ring A, The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13:542-50
   PubMed Web of Science ®Google Scholar
• Retlich S, Duval V, Graefe-Mody U, Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. J Clin Pharmacol 2010;50:873-85
   PubMed Web of Science ®Google Scholar
• Del Prato S, Barnett AH, Huisman H, Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13:258-67
   PubMed Web of Science ®Google Scholar
• Forst T, Uhlig-Laske B, Ring A, Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med 2010;27:1409-19
   PubMed Web of Science ®Google Scholar
• Taskinen MR, Rosenstock J, Tamminen I, Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:65-74
   PubMed Web of Science ®Google Scholar
• Gomis R, Espadero RM, Jones R, Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:653-61
   PubMed Web of Science ®Google Scholar
• Fonseca VA. Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr. Vivian A. Fonseca. Am J Med 2011;124:S54-61
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U, Friedrich C, Port A, Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011;13:939-46
   PubMed Web of Science ®Google Scholar
• Friedrich Ch EA, Woerle HJ, Greafe-Body U. Renal impairment has no relevant effect on long-term exposure of linagliptin in patients with type 2 diabetes mellitus. Diabetes 2011;60:abstract 1105-P
   Google Scholar
• Cooper M VEM, Emser A, Patel S, Worle HJ. Efficacy and safety of linagliptin in patients with type 2 diabetes with or without renal impairment: results from a global Phase 3 program. Diabetes 2011;60:abstract 1068-P
   Google Scholar
• Sloan L NJ. Sauce Ch, Von Eynatten M, et al. Safety and efficacy of linagliptin in type 2 diabetes patients with severe renal impairment. Diabetes 2011;60:abstract 0413-PP
   Google Scholar
• Graefe-Mody U, Rose P, Ring A, The novel DPP-4 inhibitor linagliptin can be administered to patients with various degrees of hepatic impairment without dose adjustment. J Diabetes 2011;3(Suppl 1):220
   Google Scholar
• Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother 2010;8:405-18
   PubMed Web of Science ®Google Scholar
• Mathieu C, Bollaerts K. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. Int J Clin Pract Suppl 2007;154:29-37
   PubMedGoogle Scholar
• Barzilai N, Guo H, Mahoney EM, Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011;27:1049-58
   PubMed Web of Science ®Google Scholar
• Doucet J, Chacra A, Maheux P, Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin 2011;27:863-9
   PubMed Web of Science ®Google Scholar
• Schweizer A, Dejager S, Foley JE, Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population >/=75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab 2011;13:55-64
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharmaceuticals. Efficacy and safety of linagliptin in elderly patients with type 2 diabetes. ClinicalTrialsgov [Internet] Bethesd, Md: National Library of Medicine (US) 2010; published on line 2010 may 12. NLM Identifier: NCT01084005 Available from: http://www.clinicaltrials.gov/ct2/show/NCT01 084005 [Cited 12 May 2010]
   Google Scholar